• +1-646-491-9876
    • +91-20-67278686

    Search

    Smoking Cessation - Pipeline Review, H1 2015

    Smoking Cessation - Pipeline Review, H1 2015

    • Report Code ID: RW0001172417
    • Category Pharmaceuticals
    • No. of Pages 102
    • Publication Month Jan-15
    • Publisher Name Global Markets Direct
    Smoking Cessation-Pipeline Review, H1 2015

    Summary

    Publisher's, 'Smoking Cessation-Pipeline Review, H1 2015', provides an overview of the Smoking Cessation's therapeutic pipeline.

    This report provides comprehensive information on the therapeutic development for Smoking Cessation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smoking Cessation and special features on late-stage and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

    The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

    Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

    Scope

    - The report provides a snapshot of the global therapeutic landscape of Smoking Cessation
    - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in the therapeutics development for Smoking Cessation and enlists all their major and minor projects
    - The report summarizes all the dormant and discontinued pipeline projects
    - A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - A detailed assessment of monotherapy and combination therapy pipeline projects
    - Coverage of the Smoking Cessation pipeline on the basis of target, MoA, route of administration and molecule type
    - Latest news and deals relating related to pipeline products

    Reasons to buy

    - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Identify and understand important and diverse types of therapeutics under development for Smoking Cessation
    - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
    - Devise corrective measures for pipeline projects by understanding Smoking Cessation pipeline depth and focus of Indication therapeutics
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    Table of Contents
    Table of Contents 2
    List of Tables 6
    List of Figures 7
    Introduction 8
    Global Markets Direct Report Coverage 8
    Smoking Cessation Overview 9
    Therapeutics Development 10
    Pipeline Products for Smoking Cessation-Overview 10
    Pipeline Products for Smoking Cessation-Comparative Analysis 11
    Smoking Cessation-Therapeutics under Development by Companies 12
    Smoking Cessation-Therapeutics under Investigation by Universities/Institutes 15
    Smoking Cessation-Pipeline Products Glance 16
    Clinical Stage Products 16
    Early Stage Products 17
    Unknown Stage Products 18
    Smoking Cessation-Products under Development by Companies 19
    Smoking Cessation-Products under Investigation by Universities/Institutes 20
    Smoking Cessation-Companies Involved in Therapeutics Development 21
    Aradigm Corporation 21
    Arena Pharmaceuticals, Inc. 22
    Astraea Therapeutics, LLC 23
    Bioprojet SCR 24
    Embera NeuroTherapeutics, Inc. 25
    FORUM Pharmaceuticals Inc. 26
    GlaxoSmithKline plc 27
    Invion Limited 28
    Johnson & Johnson 29
    Marinus Pharmaceuticals, Inc. 30
    NAL Pharmaceuticals Ltd. 31
    Pfizer Inc. 32
    Royalty Pharma 33
    Selecta Biosciences, Inc. 34
    Targacept, Inc. 35
    Zynerba Pharmaceuticals, Inc. 36
    Smoking Cessation-Therapeutics Assessment 37
    Assessment by Monotherapy Products 37
    Assessment by Combination Products 38
    Assessment by Target 39
    Assessment by Mechanism of Action 41
    Assessment by Route of Administration 43
    Assessment by Molecule Type 45
    Drug Profiles 47
    (oxazepam + metyrapone)-Drug Profile 47
    Product Description 47
    Mechanism of Action 47
    R&D Progress 47
    Anatabine-Drug Profile 49
    Product Description 49
    Mechanism of Action 49
    R&D Progress 49
    ARD-1600-Drug Profile 50
    Product Description 50
    Mechanism of Action 50
    R&D Progress 50
    BP-1.4979-Drug Profile 51
    Product Description 51
    Mechanism of Action 51
    R&D Progress 51
    Drugs to Inhibit FAAH for CNS Disorders-Drug Profile 52
    Product Description 52
    Mechanism of Action 52
    R&D Progress 52
    encenicline hydrochloride-Drug Profile 53
    Product Description 53
    Mechanism of Action 53
    R&D Progress 53
    ganaxolone-Drug Profile 56
    Product Description 56
    Mechanism of Action 56
    R&D Progress 56
    GSK-598809-Drug Profile 58
    Product Description 58
    Mechanism of Action 58
    R&D Progress 58
    lorcaserin hydrochloride-Drug Profile 59
    Product Description 59
    Mechanism of Action 59
    R&D Progress 59
    nadolol-Drug Profile 62
    Product Description 62
    Mechanism of Action 62
    R&D Progress 62
    NIC7-DT-Drug Profile 64
    Product Description 64
    Mechanism of Action 64
    R&D Progress 64
    nicotine-Drug Profile 65
    Product Description 65
    Mechanism of Action 65
    R&D Progress 65
    nicotine-Drug Profile 66
    Product Description 66
    Mechanism of Action 66
    R&D Progress 66
    Nicotine Vaccine-Drug Profile 67
    Product Description 67
    Mechanism of Action 67
    R&D Progress 67
    PF-05402536-Drug Profile 68
    Product Description 68
    Mechanism of Action 68
    R&D Progress 68
    PF-06413367-Drug Profile 69
    Product Description 69
    Mechanism of Action 69
    R&D Progress 69
    SEL-068-Drug Profile 70
    Product Description 70
    Mechanism of Action 70
    R&D Progress 70
    Small Molecule for Smoking Cessation-Drug Profile 72
    Product Description 72
    Mechanism of Action 72
    R&D Progress 72
    Small Molecule for Smoking Cessation and Appetite Suppression-Drug Profile 73
    Product Description 73
    Mechanism of Action 73
    R&D Progress 73
    Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation-Drug Profile 74
    Product Description 74
    Mechanism of Action 74
    R&D Progress 74
    Small Molecule to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation-Drug Profile 75
    Product Description 75
    Mechanism of Action 75
    R&D Progress 75
    Small Molecules to Agonize Alpha 4 Neuronal Nicotinic Receptor for Smoking Cessation-Drug Profile 76
    Product Description 76
    Mechanism of Action 76
    R&D Progress 76
    Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation-Drug Profile 77
    Product Description 77
    Mechanism of Action 77
    R&D Progress 77
    Smoking Cessation-Recent Pipeline Updates 78
    Smoking Cessation-Dormant Projects 90
    Smoking Cessation-Discontinued Products 91
    Smoking Cessation-Product Development Milestones 92
    Featured News & Press Releases 92
    Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation 92
    Nov 04, 2014: Lorcaserin Meets Primary Endpoint And Confirms Proof-Of-Concept As Potential Aid For Smoking Cessation In Investigational Phase II Clinical Study 93
    Nov 03, 2014: Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation 94
    Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform 95
    May 09, 2014: Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ (lorcaserin HCl) CIV by 50% 96
    Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial 96
    Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL 97
    Dec 19, 2012: Invion Provides Update On INV102 Phase II Clinical Programs 98
    Oct 17, 2012: Nabi Biopharma's Phase II Study Of NicVAX In Combination With Varenicline Does Not Meet Primary Endpoint 99
    Mar 16, 2012: Embera And Collaborators Publish Paper In Psychopharmacology Supporting EMB-001 For Smoking Cessation 99
    Appendix 101
    Methodology 101
    Coverage 101
    Secondary Research 101
    Primary Research 101
    Expert Panel Validation 101
    Contact Us 101
    Disclaimer 102

    List of Tables
    Number of Products under Development for Smoking Cessation, H1 2015 10
    Number of Products under Development for Smoking Cessation-Comparative Analysis, H1 2015 11
    Number of Products under Development by Companies, H1 2015 13
    Number of Products under Development by Companies, H1 2015 (Contd..1) 14
    Number of Products under Investigation by Universities/Institutes, H1 2015 15
    Comparative Analysis by Clinical Stage Development, H1 2015 16
    Comparative Analysis by Early Stage Development, H1 2015 17
    Comparative Analysis by Unknown Stage Development, H1 2015 18
    Products under Development by Companies, H1 2015 19
    Products under Investigation by Universities/Institutes, H1 2015 20
    Smoking Cessation-Pipeline by Aradigm Corporation, H1 2015 21
    Smoking Cessation-Pipeline by Arena Pharmaceuticals, Inc., H1 2015 22
    Smoking Cessation-Pipeline by Astraea Therapeutics, LLC, H1 2015 23
    Smoking Cessation-Pipeline by Bioprojet SCR, H1 2015 24
    Smoking Cessation-Pipeline by Embera NeuroTherapeutics, Inc., H1 2015 25
    Smoking Cessation-Pipeline by FORUM Pharmaceuticals Inc., H1 2015 26
    Smoking Cessation-Pipeline by GlaxoSmithKline plc, H1 2015 27
    Smoking Cessation-Pipeline by Invion Limited, H1 2015 28
    Smoking Cessation-Pipeline by Johnson & Johnson, H1 2015 29
    Smoking Cessation-Pipeline by Marinus Pharmaceuticals, Inc., H1 2015 30
    Smoking Cessation-Pipeline by NAL Pharmaceuticals Ltd., H1 2015 31
    Smoking Cessation-Pipeline by Pfizer Inc., H1 2015 32
    Smoking Cessation-Pipeline by Royalty Pharma, H1 2015 33
    Smoking Cessation-Pipeline by Selecta Biosciences, Inc., H1 2015 34
    Smoking Cessation-Pipeline by Targacept, Inc., H1 2015 35
    Smoking Cessation-Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 36
    Assessment by Monotherapy Products, H1 2015 37
    Assessment by Combination Products, H1 2015 38
    Number of Products by Stage and Target, H1 2015 40
    Number of Products by Stage and Mechanism of Action, H1 2015 42
    Number of Products by Stage and Route of Administration, H1 2015 44
    Number of Products by Stage and Molecule Type, H1 2015 46
    Smoking Cessation Therapeutics-Recent Pipeline Updates, H1 2015 78
    Smoking Cessation-Dormant Projects, H1 2015 90
    Smoking Cessation-Discontinued Products, H1 2015 91

    List of Figures
    Number of Products under Development for Smoking Cessation, H1 2015 10
    Number of Products under Development for Smoking Cessation-Comparative Analysis, H1 2015 11
    Number of Products under Development by Companies, H1 2015 12
    Number of Products under Investigation by Universities/Institutes, H1 2015 15
    Comparative Analysis by Clinical Stage Development, H1 2015 16
    Comparative Analysis by Early Stage Products, H1 2015 17
    Assessment by Monotherapy Products, H1 2015 37
    Number of Products by Top 10 Targets, H1 2015 39
    Number of Products by Stage and Top 10 Targets, H1 2015 39
    Number of Products by Top 10 Mechanism of Actions, H1 2015 41
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 41
    Number of Products by Top 10 Routes of Administration, H1 2015 43
    Number of Products by Stage and Top 10 Routes of Administration, H1 2015 43
    Number of Products by Top 10 Molecule Types, H1 2015 45
    Number of Products by Stage and Top 10 Molecule Types, H1 2015 45
    Aradigm Corporation
    Arena Pharmaceuticals, Inc.
    Astraea Therapeutics, LLC
    Bioprojet SCR
    Embera NeuroTherapeutics, Inc.
    FORUM Pharmaceuticals Inc.
    GlaxoSmithKline plc
    Invion Limited
    Johnson & Johnson
    Marinus Pharmaceuticals, Inc.
    NAL Pharmaceuticals Ltd.
    Pfizer Inc.
    Royalty Pharma
    Selecta Biosciences, Inc.
    Targacept, Inc.
    Zynerba Pharmaceuticals, Inc.

    Request for Sample

    Report Url http://www.reportsweb.com//smoking-cessation-pipeline-review-h1-2015&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//smoking-cessation-pipeline-review-h1-2015&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//smoking-cessation-pipeline-review-h1-2015&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments